Rheumatoid arthritis is a painful autoimmune disease where the immune system attacks the joints. But what if the key driver of that inflammation is a simple molecule your body makes naturally? A new review of the science suggests that succinate, a molecule normally involved in energy production, may be a major culprit.
The review looked at how succinate builds up in the joints of people with RA. It found three ways this happens: the mitochondria (the cell's power plants) can't break it down properly, the body makes extra succinate through alternative pathways, and more succinate gets pushed out of cells into the surrounding space. Once there, succinate triggers inflammation through three separate mechanisms: it binds to a receptor called SUCNR1, it stabilizes a protein called HIF-1α inside cells, and it acts as an epigenetic modulator, changing how genes are read.
This is early work. The review is a summary of lab studies, not a clinical trial in people. But it offers a clear roadmap for developing new treatments. Drugs that block SUCNR1 or succinate dehydrogenase (an enzyme involved in succinate breakdown) could potentially calm the inflammation in RA. Combining these with existing anti-inflammatory drugs might work even better. For now, these are ideas, not proven therapies. But for the millions living with RA, this research points to a fresh approach.
